Incidence	incidence	O	O	O	O
of	of	O	O	O	O
neoplasms	neoplasms	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
exposed	exposed	O	O	O	O
to	to	O	O	O	O
different	different	O	O	O	O
treatment	treatment	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

Immunosuppressive	immunosuppressive	O	O	O	O
drugs	drugs	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
used	used	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
last	last	O	O	O	O
30	30	O	O	O	O
years	years	O	O	O	O
in	in	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
drugs	drugs	O	O	O	O
commonly	commonly	O	O	O	O
used	used	O	O	O	O
are	are	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
chlorambucil	chlorambucil	O	O	OTHERS	I
(	(	O	O	O	O
alkylating	alkylating	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
azathioprine	azathioprine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
purine	purine	O	O	OTHERS	I
analogue	analogue	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
methotrexate	methotrexate	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
folic	folic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
analogue	analogue	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
is	is	O	O	O	O
evidence	evidence	O	O	O	O
that	that	O	O	O	O
all	all	O	O	O	O
four	four	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
drugs	drugs	O	O	O	O
can	can	O	O	O	O
reduce	reduce	O	O	O	O
synovitis	synovitis	O	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
disease	disease	O	O	O	O
activity	activity	O	O	O	O
almost	almost	O	O	O	O
always	always	O	O	O	O
recurs	recurs	O	O	O	O
after	after	O	O	O	O
therapy	therapy	O	O	O	O
is	is	O	O	O	O
stopped	stopped	O	O	O	O
.	.	O	O	O	O

Since	since	O	O	O	O
adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
are	are	O	O	O	O
frequent	frequent	O	O	O	O
,	,	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
50	50	O	O	O	O
percent	percent	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
are	are	O	O	O	O
able	able	O	O	O	O
to	to	O	O	O	O
continue	continue	O	O	O	O
a	a	O	O	O	O
particular	particular	O	O	O	O
drug	drug	O	O	O	O
for	for	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
one	one	O	O	O	O
year	year	O	O	O	O
.	.	O	O	O	O

Since	since	O	O	O	O
it	it	O	O	O	O
takes	takes	O	O	O	O
three	three	O	O	O	O
to	to	O	O	O	O
12	12	O	O	O	O
months	months	O	O	O	O
to	to	O	O	O	O
achieve	achieve	O	O	O	O
maximal	maximal	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
those	those	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
are	are	O	O	O	O
unable	unable	O	O	O	O
to	to	O	O	O	O
continue	continue	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
receive	receive	O	O	O	O
little	little	O	O	O	O
benefit	benefit	O	O	O	O
from	from	O	O	O	O
it	it	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
alkylating	alkylating	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
have	have	O	O	O	O
an	an	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
acute	acute	O	O	OTHERS	I
nonlymphocytic	nonlymphocytic	O	O	OTHERS	I
leukemia	leukemia	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
both	both	O	O	O	O
alkylating	alkylating	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
azathioprine	azathioprine	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
non-Hodgkin	non-hodgkin	O	O	O	O
's	's	O	O	O	O
lymphoma	lymphoma	O	O	OTHERS	I
.	.	O	O	O	O

Cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
increases	increases	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
carcinoma	carcinoma	O	DISEASE	OTHERS	I
of	of	O	O	O	O
the	the	O	O	O	O
bladder	bladder	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
several	several	O	O	O	O
long-term	long-term	O	O	O	O
studies	studies	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
treated	treated	O	O	O	O
with	with	O	O	O	O
azathioprine	azathioprine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
most	most	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
common	common	O	O	O	O
cancers	cancers	O	DISEASE	OTHERS	I
is	is	O	O	O	O
not	not	O	O	O	O
increased	increased	O	O	O	O
.	.	O	O	O	O

Data	data	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
malignancy	malignancy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
are	are	O	O	O	O
still	still	O	O	O	O
being	being	O	O	O	O
collected	collected	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
until	until	O	O	O	O
further	further	O	O	O	O
information	information	O	O	O	O
is	is	O	O	O	O
available	available	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
particularly	particularly	O	O	O	O
alkylating	alkylating	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
reserved	reserved	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
progressive	progressive	O	O	O	O
disease	disease	O	O	O	O
or	or	O	O	O	O
life-threatening	life-threatening	O	O	O	O
complications	complications	O	O	O	O
.	.	O	O	O	O

